Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia

October 1^st sees the PBS listing of REXULTI, a novel antipsychotic indicated for the treatment of adults with schizophrenia.

Patient Group Input Submissions: Brexpiprazole (Rexulti) - NCBI Bookshelf

Introducing REXULTI® (brexpiprazole): a new PBS-listed antipsychotic for schizophrenia

Brexpiprazole - Mechanism of Action and Clinical Application

Otsuka and Lundbeck Announce U.S. Food and Drug Administration (FDA) Approval of Supplemental New Drug Application (sNDA) for REXULTI® ( brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer's Disease

For Alzheimer's Agitation, Promising News from Rexulti (Brexpiprazole)

FDA Approves New Schizophrenia, Depression Drug Brexpiprazole - Psychiatry Advisor

Rexulti.PDF

Table 2 from Brexpiprazole (Rexulti): A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder.

Full article: In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole

Brexpiprazole: A Newly Approved Atypical Antipsychotic Agent

The Visual Illusion of Efficacy in Psychiatric Drug Trials - Mad In America